2021
Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015
Sun J, Althoff KN, Jing Y, Horberg MA, Buchacz K, Gill MJ, Justice AC, Rabkin CS, Goedert JJ, Sigel K, Cachay E, Park L, Lim JK, Kim HN, Re V, Moore R, Sterling T, Peters MG, Achenbach CJ, Silverberg M, Thorne JE, Mayor AM, Crane HM, Kitahata MM, Klein M, Kirk GD. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Network Open 2021, 4: e2037512. PMID: 33595662, PMCID: PMC7890526, DOI: 10.1001/jamanetworkopen.2020.37512.Peer-Reviewed Original ResearchConceptsHCC incidence ratesHigher HCC riskHepatitis C virusHepatitis B virusModern cART eraCD4 cell countIncidence rateCART eraHCC riskHepatocellular carcinomaCohort studyTriple infectionNorth American AIDS Cohort CollaborationCell countAvailable CD4 cell countHigher HIV RNA levelsLow CD4 cell countsCombination antiretroviral therapy eraDiagnosis of HCCAnti-HCV seropositivityAntiretroviral therapy eraHBV-HCV coinfectionRecent HIV RNAHIV RNA levelsHBV e antigen
2018
Past year and prior incarceration and HIV transmission risk among HIV-positive men who have sex with men in the US*
Khan MR, McGinnis KA, Grov C, Scheidell JD, Hawks L, Edelman EJ, Fiellin DA, McInnes DK, Braithwaite RS, Justice AC, Wang EA. Past year and prior incarceration and HIV transmission risk among HIV-positive men who have sex with men in the US*. AIDS Care 2018, 31: 349-356. PMID: 30064277, PMCID: PMC6699634, DOI: 10.1080/09540121.2018.1499861.Peer-Reviewed Original ResearchConceptsHIV-positive MSMSex risk behaviorsViral loadSubstance useDrug useRisk behaviorsNon-injection drug useTransmission riskMultiple sex partnershipsDetectable viral loadHIV viral loadHIV transmission riskInjection drug useNew HIV infectionsHIV-positive menPrior incarcerationHealth care programsHIV infectionClinical outcomesPast yearCare programSociodemographic factorsSocial determinantsRisk determinantsMSM
2017
DNA methylation signatures of illicit drug injection and hepatitis C are associated with HIV frailty
Zhang X, Hu Y, Justice AC, Li B, Wang Z, Zhao H, Krystal JH, Xu K. DNA methylation signatures of illicit drug injection and hepatitis C are associated with HIV frailty. Nature Communications 2017, 8: 2243. PMID: 29269866, PMCID: PMC5740109, DOI: 10.1038/s41467-017-02326-1.Peer-Reviewed Original ResearchConceptsIllicit drug injectionHepatitis C infectionWhite blood cellsIllicit drug useCo-occurring conditionsMethylation signaturesDiscovery sampleC infectionHepatitis CEpigenome-wide association analysisLower frailtyDrug injectionHigh frailtyImmune functionHealth outcomesDrug useFrailtyDNA methylation signaturesBlood cellsHIVReplication sampleEpigenetic programmingSignificant CpGsEpigenetic effectsIndividuals
2015
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals
May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte A, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 348-354. PMID: 25848927, PMCID: PMC4506784, DOI: 10.1097/qai.0000000000000603.Peer-Reviewed Original ResearchConceptsInjection drug useDrug useLiver-related mortalityHepatitis C infectionEffect of HCVMortality hazard ratioNorth American cohortHCV coinfectionHCV statusAntiretroviral therapyC infectionHepatitis CHazard ratioSurvival differencesRisk factorsExcess mortalityPoor survivalRisk groupsHCVAmerican cohortHIVNew treatmentsMortalitySubstantial proportionComplete data
2013
Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals
Lucas G, Jing Y, Sulkowski M, Abraham A, Estrella M, Atta M, Fine D, Klein M, Silverberg M, Gill M, Moore R, Gebo K, Sterling T, Butt A, for the NA-ACCORD of the IeDEA, Kirk G, Benson C, Bosch R, Collier A, Boswell S, Grasso C, Mayer K, Hogg R, Harrigan R, Montaner J, Cescon A, Brooks J, Buchacz K, Gebo K, Moore R, Carey J, Rodriguez B, Horberg M, Silverberg M, Horberg M, Thorne J, Goedert J, Jacobson L, Klein M, Rourke S, Burchell A, Rachlis A, Rico P, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Patel P, Brooks J, Saag M, Mugavero M, Willig J, Eron J, Napravnik S, Kitahata M, Crane H, Justice A, Dubrow R, Fiellin D, Sterling T, Haas D, Bebawy S, Turner M, Gange S, Anastos K, Moore R, Saag M, Gange S, Kitahata M, McKaig R, Justice A, Freeman A, Moore R, Freeman A, Lent C, Kitahata M, Van Rompaey S, Crane H, Webster E, Morton L, Simon B, Gange S, Althoff K, Abraham A, Lau B, Zhang J, Jing J, Golub E, Modur S, Hanna D, Rebeiro P, Wong C, Mendes A. Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. The Journal Of Infectious Diseases 2013, 208: 1240-1249. PMID: 23904290, PMCID: PMC3778973, DOI: 10.1093/infdis/jit373.Peer-Reviewed Original ResearchConceptsStage 3 CKDStage 5 CKDProgressive CKDAviremic subjectsHazard ratioGlomerular filtration rate decreaseChronic kidney disease riskHepatitis C virus replicationHCV seronegative subjectsHCV viremic subjectsAdjusted hazard ratioChronic kidney diseaseHepatitis C viremiaKidney disease riskConfidence intervalsC virus replicationAdvanced CKDAviremic individualsCKD incidenceHCV-viremicSeronegative subjectsC viremiaViremic subjectsKidney diseaseCKD
2011
The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis
Murray M, Hogg R, Lima V, May M, Moore D, Abgrall S, Bruyand M, Monforte A, Tural C, Gill M, Harris R, Reiss P, Justice A, Kirk O, Saag M, Smith C, Weber R, Rockstroh J, Khaykin P, Sterne J, Collaboration F. The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Medicine 2011, 13: 89-97. PMID: 21819529, PMCID: PMC4539012, DOI: 10.1111/j.1468-1293.2011.00940.x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountCohort StudiesDisease ProgressionDrug Therapy, CombinationDrug UsersFemaleHIV InfectionsHumansMaleMiddle AgedOdds RatioProportional Hazards ModelsRisk FactorsRNA, ViralSubstance Abuse, IntravenousViral LoadYoung AdultConceptsCombination antiretroviral therapyCD4 cell countBaseline CD4 cell countDisease progressionCell countCART initiationAntiretroviral therapyHigher baseline HIV viral loadLower baseline CD4 cell countBaseline HIV viral loadSpecific causesART Cohort CollaborationLiver-related deathHIV viral loadHIV-positive individualsRisk of deathCause of deathDrug use historyCohort CollaborationCohort studyCumulative incidenceHazard ratioHIV diseaseClinical AIDSPrior diagnosis
2009
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries
Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, Gill J, Fätkenheuer G, Lewden C, Saag M, Staszewski S, d'Arminio Monforte A, Casabona J, Lampe F, Justice A, von Wyl V, Egger M. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. International Journal Of Epidemiology 2009, 38: 1624-1633. PMID: 19820106, PMCID: PMC3119390, DOI: 10.1093/ije/dyp306.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCause of DeathCD4 Lymphocyte CountCohort StudiesFemaleHIVHIV InfectionsHomosexuality, MaleHumansMaleMortalityPrevalenceProspective StudiesRisk FactorsSubstance Abuse, IntravenousViral LoadVirus ReplicationConceptsCD4 cell countAntiretroviral therapyCells/microLGeneral populationCell countEligible patientsExcess mortalityCopies/Start of ARTViral replicationART Cohort CollaborationCorresponding general populationMortality of HIVPotent antiretroviral therapyCombination antiretroviral therapyPercentage of patientsProspective cohort studyInjection drug useViral load measurementsNumber of deathsCohort CollaborationCohort studyMedian ageViral loadClinical stage
2006
Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort
Braitstein P, Justice A, Bangsberg DR, Yip B, Alfonso V, Schechter MT, Hogg RS, Montaner J. Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. AIDS 2006, 20: 323-331. PMID: 16439865, DOI: 10.1097/01.aids.0000198091.70325.f4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlbuminsAntiretroviral Therapy, Highly ActiveCohort StudiesFemaleHepatitis CHIV InfectionsHIV-1HumansMaleOdds RatioPatient ComplianceSex FactorsSubstance Abuse, IntravenousConceptsInjection drug useAntiretroviral treatmentAntiretroviral therapyLiver injuryHigher plasma albumin levelCombination antiretroviral treatmentHepatitis C serostatusHepatitis C coinfectionPlasma albumin levelsMultivariate logistic regressionDrug treatment programsHIV/AIDSHCV seropositivityC coinfectionHCV antibodiesHIV cohortHCV serologyAlbumin levelsLow albuminPrimary outcomePrescription refillsPoor adherenceMale genderHIV therapyEligible individuals